Novel strategies of protecting non-cancer cells during chemotherapy: Are they ready for clinical testing?

Oncotarget

Volumn 2, Issue 3, 2011, Pages 107-108

  Darzynkiewicz, Zbigniew ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; NOCODAZOLE; NUTLIN 3; PACLITAXEL; PROTEIN P53; RAPAMYCIN; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL PROTECTION; HUMAN; NOTE; CELL GROWTH; DRUG EFFECT; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 79960462101     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.249     Document Type: Note

References (12)

1. Wikipedia, http://en.wikipedia.org/wiki/Targeted_therapy
2. Muller BA. Imatinib and its successors - how modern chemistry has changed drug development. Curr. Pharm. Des. 2009; 15:120-33.
3. Blagosklonny MV, Darzynkiewicz Z. Why Iressa failed? Toward novel use of kinase inhibitors. Canc Biol Ther 2003; 2:137-40
4. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974; 71:1286-90.
5. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: Protection of normal cells and unshielding of cancer cells. Cell Cycle 2002; 1: 375-82.
6. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of and Actinomycin D/ VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget 2010; 1:639-50.
7. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2: this issue
8. Choong ML, Yang H, Lee MA, Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 cyclotherapy. Cell Cycle 2009; 8:2810-8
9. Clements A, Gao B, Yeap SH, Wong MK, Ali SS, Gurney H. Metformin in prostate cancer: two for the price of one. Ann Oncol 2011; Mar18 (Epub)
10. Zhuang Y, Miskimins K. Metformin induces both caspasedependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 2011; Mar 11 (Epub)
11. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2011 Feb 8 (Epub)
12. Halicka DH, Ardelt B, Li X, Melamed MR, Darzynkiewicz Z. 2-deoxyglucose enhances sensitivity of human histiocytic U-935 cells to apoptosis induced by Tumor Necrosis Factor. Cancer Res 1995; 55:444-9.